Protara Therapeutics
TARA
44 hedge funds and large institutions have $126M invested in Protara Therapeutics in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 6 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
8% less funds holding
Funds holding: 48 → 44 (-4)
22% less capital invested
Capital invested by funds: $161M → $126M (-$34.7M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$1.51M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$1.19M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$947K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$120K |
| 5 |
State Street
Boston,
Massachusetts
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$448K |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$377K |
| 3 |
SIM
Spark Investment Management
New York
|
-$269K |
| 4 |
Morgan Stanley
New York
|
-$60.1K |
| 5 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$48K |
TARA Hedge Fund Activity: Q3 2015 in Review
44 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2015, worth a combined $126M — down 22% from $161M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TARA and 2 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 12 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $1.51M. The largest seller was Vanguard Group, cutting an estimated $448K.
- 44 institutional investors held Protara Therapeutics (TARA) as of Q3 2015, down from 48 in Q2 2015.
- Funds reported $126M of Protara Therapeutics stock for Q3 2015, down 22% quarter-over-quarter.
- 2 funds opened new Protara Therapeutics positions in Q3 2015 and 6 closed out, a net change of -4 holders.
- The largest Protara Therapeutics buyer in Q3 2015 was Baker Bros. Advisors, an estimated $1.51M added.
- The largest Protara Therapeutics seller in Q3 2015 was Vanguard Group, an estimated $448K sold.
Based on aggregated 13F filings for Q3 2015.